Eli Lilly and Ribozyme Pharmaceuticals Collaborate to Develop Novel Anti-Hepatitis C Treatment

Strategic Insights -

Eli Lilly and Company, a global research-based pharmaceutical corporation, and Ribozyme Pharmaceuticals, Inc., a leader in ribozyme therapeutic development, have announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for the development of a novel anti-Hepatitis C treatment, LY466700. This treatment has shown promise in preclinical studies, demonstrating the ability to specifically cleave Hepatitis C virus (HCV) RNA and inhibit viral replication.

Key Takeaways:

  • The IND application for LY466700, a chemically synthesized ribozyme designed to target HCV RNA, has been submitted to the FDA for a clinical study in normal volunteers and HCV-infected patients.
  • LY466700 has shown efficacy in preclinical studies, including specific inhibition of HCV-poliovirus replication in cell culture and uptake by liver cells in mice.
  • The treatment is expected to be effective against all known HCV genotypes and even after infection or replication has been established.
  • Hepatitis C is a significant health concern, with over 4 million people infected in the U.S. and 125 million worldwide; current treatments have limited efficacy and can cause serious side effects.
  • The development of LY466700 addresses an unmet medical need for effective management of HCV disease.
  • Lilly and RPI are collaborating to accelerate the development of LY466700, with the goal of bringing this novel treatment to patients.

Statistics:

  • Over 4 million people are infected with Hepatitis C in the U.S.
  • 125 million people are reported to be infected worldwide.
  • Current treatments for HCV have a clearance rate of only 20-40%.
  • HCV is considered an epidemic by the Center for Disease Control.

Sources:

  • "Eli Lilly and Company and Ribozyme Pharmaceuticals, Inc. Announce Approval to Begin Clinical Testing of RPI's Anti-Hepatitis C Ribozyme, LY466700" (PRNewswire, January 11)
  • "Ribozymes: Therapeutic Enzymes of the Future" (American Association for the Study of Liver Disease conference)
  • Eli Lilly and Company Securities and Exchange Commission filings, including Forms 10-K and 10-Q.